Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CEST
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
01:14p CVS HEALTH : Opens Employment and Training Facility to Serve Fort Bragg Military..
07/20 CVS HEALTH : Opens Employment And Training Facility To Serve Fort Bragg Military..
07/20 CVS HEALTH : ex-dividend day
07/19 CVS HEALTH - STUDY : Using Big Data to Help Curb Prescription Opioid Misuse
07/18 CVS HEALTH : Personal Capital Advisors Has Lowered Cvs Health (CVS) Stake By $81..
07/18 CVS HEALTH : Increasing Quality, Lowering Costs at the State Level
07/15 CVS HEALTH : Raimondo Announces Partnership With CVS Health to Fight Opioid Epid..
07/14 CVS : Employing Multiple Strategies to Address Medication Adherence
07/13 CVS HEALTH : gives $250,000 to Woonsocket nonprofit to treat people addicted to ..
07/12 CVS HEALTH CORP (NYSE : CVS) MinuteClinic Joins Alere eScreen Occupational Healt..
More news
News from SeekingAlpha
07/21 DIVGRO PULSE : July 2017
07/21 Vanguard Prepares To Destroy The S&P 500 Again
07/21 Guilt By Association Is Affecting Stocks - Cramer's Mad Money (7/20/17)
07/19 Red Numbers In Your Portfolio Can Be Scary, But They Don't Have To Be
07/19 RITE AID : Where Do We Go From Here?
Financials ($)
Sales 2017 184 151 M
EBIT 2017 10 162 M
Net income 2017 5 376 M
Debt 2017 24 615 M
Yield 2017 2,56%
P/E ratio 2017 14,93
P/E ratio 2018 13,11
EV / Sales 2017 0,56x
EV / Sales 2018 0,53x
Capitalization 78 478 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 87,2 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-2.38%78 478
WALGREENS BOOTS ALLIANCE-4.66%84 431
EXPRESS SCRIPTS HOLDING CO-9.14%37 520
MCKESSON CORPORATION18.13%35 085
CARDINAL HEALTH INC6.00%24 099
AMERISOURCEBERGEN CORP.17.18%20 006